This approval is expected, so I am curious whether it will have much effect on the stock price... I of course hope so, but with the shorts in full gear one never knows. The shorts should be in retreat very soon, but I wouldn't be surprised if it wasn't one to two months before that happens.
Couple of questions, can BRLI sell and distribute Rolapitant? Adding a product to BRLI's list would be great for revenue increases. How about Eirgen's products, could they be sold by BRLI as well? I have no idea, just putting it out there.
Excluding the shorts and their monkey business messing with the stock price, the next earnings report should have at least three changes: 4K Score being sold by BRLI, more 4K Score reimbursement deals finalized and Rolapitant on the market or in process. I'd imagine that the CPT Code and insurance reimbursement for Rolapitant will take many months to worked out.
One question though, can BRLI sell and distribute Rolapitant? Adding a product to BRLI's list would be great for revenue increases. How about Eirgen's products, could they be sold by BRLI as well? I have no idea, just putting it out there.
With things getting wacky I wonder if Marty will be off? I would think that pharma would be a safe haven, certain from exposure to China. It will be interesting to see what happens this week. The Chinese are going to start panicking even more here soon, my guess is another devaluation of their currency will be coming. At the end of September, depending on where this stock is, I might do an short-term options trade betting that this stock moves up through October on the run up to the earnings call. If we hit $11 or $10, I would think that once the market stabilizes and 2016 gets close that $14 - $15 should not be out of the question.
Sorry Bud, I get how it feels, but it was bound to happen eventually. I want the market to get whatever out of its system. OPKO will keep growing in the meantime. BRLI acquisition feels to me like a magnifier of the growth that will be. Very excited for 2016.
Chuck, I like the way you think. I have decided to move into some Calls a month or two out if the stock price holds down here for a couple of more weeks. If it goes up before then, great.
(Maybe I did not understand the part about the "definitive merger agreement", I was thinking that this would be after the vote.)
Reference common stock, implying a value of $48.35 of OPKO common stock for each share of Bio-Reference common stock based upon the closing price of OPKO common stock on May 21, 2015. Based upon such closing price, this proposal reflected a premium of 43.2% to the closing price of Bio-Reference common stock on May 21, 2015. Drs. Grodman and Frost agreed to recommend this level of merger consideration to their respective boards of directors. Following this conversation, Dr. Grodman contacted Dr. Frost and indicated that, were the closing price of OPKO common stock to decrease, prior to the execution of a definitive merger agreement, such that the implied value of the merger consideration fell below $43.50 per share of Bio-Reference common stock, Bio-Reference would expect an upward adjustment of the exchange ratio to ensure that the implied value of the merger consideration equaled or exceeded $43.50 per share prior to the execution of a definitive merger agreement.
When seeing the stock price of OPK slide it makes me wonder who would benefit for this slide besides shorts.
Right now the conversion would work out to about 3.25 shares of OPK for every BRLI share. It is interesting that BRLI, based in New Jersey, just like many shorts, are the ones to benefit.
OPKO believes what? I find your post confusing as I thought that OPKO did not state any such thing.
It couldn't have been more obvious seeing the shorts taking out stops, shorting then covering, then shorting some more then covering. Damn I wished they would get steamrolled by some amazing news. I only care that I have 2,000 shares of my small position left at the end of 2017 (minus any stock splits).
Learning is not the point with these guys. Making a buck or two for every reply they get is.
In my opinion, the recent Motley Fool article missed important items and is a paid bash or at best just a quick piece of #$%$ thrown together. Let us not forget how Motley Fool got its start as being paid to write about companies.
"Rayaldee could generate north of a half-billion in peak annual sales." Really? Peak sales? Where the heck did the author get this? Try adding a billion or two to this number, probably much, much more. What about 4K Score? No mention of that.
I am not the most tech savvy but I find comparing these two companies interesting.
-CyPhy does very small personal drones for troops. I think this is needed since just focusing on the large vehicle based drones ignores the needs of combat troops if they want to expand their view. Special Forces could benefit from this obviously. These are lower cost and easier to justify buying.
-CyPhy has six arms, not four like DRNE. For the larger drones having six arms for propellers could be more stable, but more weight as well. DRNE's four arms with two propellers for each arm looks robust, but for smaller drones that fit in someone's pocket you would want something that could be folded up.
-CyPhy does Kickstarter to fund projects. This is smart where they do a personal drone for the consumer market, have the consumer fund it, which also allows them to fund development of their real product development.
-DRNE seems to have larger drones that satisfy a different part of the market but CyPhy sounds to be addressing this exact market that DRNE is working with CNN on.
CyPhy toutes their amazing Hi Res cameras. Wondering if DRNE has the same capability.
DRNE seems to be working hard at what they do,